Literature DB >> 18088444

Virulence factors in brucellosis: implications for aetiopathogenesis and treatment.

Emilie Fugier1, Georgios Pappas, Jean-Pierre Gorvel.   

Abstract

Brucella species are responsible for the global zoonotic disease brucellosis. These intracellular pathogens express a set of factors - including lipopolysaccharides, virulence regulator proteins and phosphatidylcholine - to ensure their full virulence. Some virulence factors are essential for invasion of the host cell, whereas others are crucial to avoid elimination by the host. They allow Brucella spp. to survive and proliferate within its replicative vacuole and enable the bacteria to escape detection by the host immune system. Several strategies have been used to develop animal vaccines against brucellosis, but no adequate vaccine yet exists to cure the disease in humans. This is probably due to the complicated pathophysiology of human Brucella spp. infection, which is different than in animal models. Here we review Brucella spp. virulence factors and how they control bacterial trafficking within the host cell.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18088444     DOI: 10.1017/S1462399407000543

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  17 in total

Review 1.  Bacterial manipulation of innate immunity to promote infection.

Authors:  Lautaro Diacovich; Jean-Pierre Gorvel
Journal:  Nat Rev Microbiol       Date:  2010-02       Impact factor: 60.633

2.  Mechanism of Asp24 upregulation in Brucella abortus rough mutant with a disrupted O-antigen export system and effect of Asp24 in bacterial intracellular survival.

Authors:  Mingxing Tian; Jing Qu; Xiangan Han; Chan Ding; Shaohui Wang; Daxin Peng; Shengqing Yu
Journal:  Infect Immun       Date:  2014-04-21       Impact factor: 3.441

Review 3.  The current therapeutical strategies in human brucellosis.

Authors:  Mile Bosilkovski; Fariba Keramat; Jurica Arapović
Journal:  Infection       Date:  2021-03-01       Impact factor: 3.553

4.  Blocking the expression of syntaxin 4 interferes with initial phagocytosis of Brucella melitensis in macrophages.

Authors:  Alfredo Castañeda-Ramírez; Diana González-Rodríguez; J Aide Hernández-Pineda; Antonio Verdugo-Rodríguez
Journal:  Can J Vet Res       Date:  2015-01       Impact factor: 1.310

5.  Importance of Lipopolysaccharide and Cyclic β-1,2-Glucans in Brucella-Mammalian Infections.

Authors:  Andreas F Haag; Kamila K Myka; Markus F F Arnold; Paola Caro-Hernández; Gail P Ferguson
Journal:  Int J Microbiol       Date:  2010-12-01

6.  Comparison of a New and Rapid Method: Brucella Coombs Gel Test With Other Diagnostic Tests.

Authors:  Fatma Kalem; Ayşe Gül Ergün; Süleyman Durmaz; Metin Doğan; Ömür Ertuğrul; Seval Gündem
Journal:  J Clin Lab Anal       Date:  2016-03-17       Impact factor: 2.352

7.  Exploiting the Campylobacter jejuni protein glycosylation system for glycoengineering vaccines and diagnostic tools directed against brucellosis.

Authors:  Jeremy A Iwashkiw; Messele A Fentabil; Amirreza Faridmoayer; Dominic C Mills; Mark Peppler; Cecilia Czibener; Andres E Ciocchini; Diego J Comerci; Juan E Ugalde; Mario F Feldman
Journal:  Microb Cell Fact       Date:  2012-01-25       Impact factor: 5.328

8.  Evaluation of recombinant invasive, non-pathogenic Eschericia coli as a vaccine vector against the intracellular pathogen, Brucella.

Authors:  Jerome S Harms; Marina A Durward; Diogo M Magnani; Gary A Splitter
Journal:  J Immune Based Ther Vaccines       Date:  2009-01-06

Review 9.  A history of the development of Brucella vaccines.

Authors:  Eric Daniel Avila-Calderón; Ahidé Lopez-Merino; Nammalwar Sriranganathan; Stephen M Boyle; Araceli Contreras-Rodríguez
Journal:  Biomed Res Int       Date:  2013-06-03       Impact factor: 3.411

10.  Substrate-specific gene expression in Batrachochytrium dendrobatidis, the chytrid pathogen of amphibians.

Authors:  Erica Bree Rosenblum; Thomas J Poorten; Suzanne Joneson; Matthew Settles
Journal:  PLoS One       Date:  2012-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.